Obesity Medication CagriSema May Support Weight Loss
New trial data suggests this treatment effectively promotes weight loss in women across all reproductive stages.
Updated on Oct. 29, 2026 in Weight Loss
Live Poll
Should weight-loss treatment plans be personalized according to a person's reproductive stage?
New trial analysis suggests that the investigational obesity medication CagriSema effectively reduces weight in women across different reproductive life stages. Participants with overweight or obesity without type 2 diabetes saw significant weight loss over a 68-week period.
Why it matters
Researchers are investigating how hormonal shifts associated with aging and reproductive status influence the efficacy of obesity treatments. This analysis helps clarify how therapy outcomes may vary for women transitioning through menopause.
In a post hoc analysis of the 2,309-participant REDEFINE 1 trial, women receiving once-weekly CagriSema achieved 25% average weight loss at 68 weeks. While findings show promise, researchers note that further prospective studies are needed to confirm these results across the reproductive lifespan.
The players
The Menopause Society
An organization of health professionals dedicated to managing the health and quality of life of women as they approach and pass through menopause.
Mayo Clinic
A nonprofit academic medical center focused on integrated clinical practice, education, and research in chronic disease management.
The details
CagriSema combines the long-acting GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide. This dual-action approach targets multiple pathways in the brain to regulate appetite and energy balance. The analysis found that 68.7% of women in the CagriSema group lost at least 20% of their body weight, alongside improvements in systolic blood pressure and LDL cholesterol levels.
Timeline
The clinical trial duration lasted 68 weeks.
The findings were presented in October 2026.
Health Landscape
This analysis builds upon the REDEFINE 1 clinical trial program, which continues to evaluate next-generation weight management therapies. It highlights a shift in clinical research toward understanding how sex-specific factors and hormonal changes influence the effectiveness of obesity medications.
If you are considering obesity medication, discuss your full health history and reproductive status with your physician to understand potential treatment pathways. Understanding how these therapies may impact cardiovascular markers like blood pressure is also a key part of these clinical conversations.
The takeaway
CagriSema shows consistent weight loss potential in clinical analyses across various reproductive stages. Women interested in medical weight management should consult their doctor to evaluate which clinical options align with their individual health profile and metabolic needs.
Further reading
For more on evolving approaches to weight management, visit our Weight Loss section.
Source note: This article includes information reported by Healio.
Live Poll
Should weight-loss treatment plans be personalized according to a person's reproductive stage?
